Schizophrenia is known to have a wide variety of cognitive deficits which may precede psychosis and are associated with substantial functional impairment. There remains an unmet need to address these symptoms. A biopharmaceutical team was investigating the effect of their novel therapeutic compound KarXT (xanomeline-trospium) on cognition in schizophrenia across a 5-week, double-blind, placebo-controlled Phase 2 trial.
125 patients took the Cogstate Brief Battery at baseline and endpoint. Data analysis from the Cogstate digital tests revealed that significant treatment effects were observed among patients with cognitive impairment. Data results suggested the therapeutic compound had a separable and meaningful impact on cognition for schizophrenia patients with cognitive impairment.
Sauder et al., Translation Psychiatry (2022) https://doi.org/10.1038/s41398-022-02254-9.
